Assessment of Endocrine, Metabolic, and Fibrinolytic Profile and Its Association with BMI in Polycystic Ovarian Syndrome
Life Sciences-Physiology
DOI:
https://doi.org/10.22376/ijlpr.2023.13.2.L31-L38Keywords:
Polycystic ovarian syndrome, Metformin, Hyper AndrogenismAbstract
Polycystic ovarian syndrome is a typical endocrine disorder that occurs in women and has a significant impact on the reproductive, metabolic, endocrine, and fibrinolytic systems. It is a heterogeneous clinical condition caused by multiple factors, especially obesity. Furthermore, metformin is the classical treatment approach for PCOS, which has conflicted results. The current study aimed to find out the effect of the usage of metformin on metabolic, fibrinolytic, and reproductive profiles between obese women with PCOS and non-obese women with PCOS. A cross-sectional study was carried out on 200 women diagnosed with PCOS and divided into two groups based on BMI. Each group was further subdivided into three subgroups (A, B, and C) based on their prescribed treatment. In addition, 50 age-matched controls were selected to compare the outcome. The reproductive hormones, lipid profile, glycaemic index, and fibrinolytic profile were measured in each group and compared to find the desired association. The demographic variables did not show significant variation within or between the groups except BMI. Group IA has shown better metabolic variables, Group IB has an improved endocrine profile, and Group IC has a better fibrinolytic profile(p>0.01**). Group II B has shown a better metabolic and endocrine profile, whereas it is significantly higher in the fibrinolytic profile (p>0.01**). Cumulatively Group II has a drastic reduction in all variables than group I(p>0.01**) except few non-significant variables. Obese PCOS patients are at an increased risk for complications such as endometrial hyperplasia, metabolic syndrome, and vascular thrombosis. Metformin and OCP are highly beneficial as they reduce the risk of insulin resistance and glucose intolerance and improve ovarian functions for a better reproductive life.
References
Wolf WM, Wattick RA, Kinkade ON, Olfert MD. Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity. Int J Environ Res Public Health. 2018 Nov;15(11):2589. doi: 10.3390/ijerph15112589, PMID 30463276.
Roe AH, Dokras A. The diagnosis of polycystic ovary syndrome in adolescents. Rev Obstet Gynecol. 2011;4(2):45-51. PMID 22102927.
Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome-part 1. Endocr Pract. 2015 Nov 1;21(11):1291-300. doi: 10.4158/EP15748. DSC, PMID 26509855.
Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018 May;14(5):270-84. doi: 10.1038/nrendo.2018.24, PMID 29569621.
Rossmanith WG, Wirth U, Benz R, Wolf AS. Endocrine dynamics during pulsatile GnRH administration in patients with hypothalamic amenorrhea and polycystic ovarian disease. Gynecol Endocrinol. 1989 Jan 1;3(1):21-34. doi: 10.3109/09513598909152449, PMID 2658471.
Targher G, Zoppini G, Bonora E, Moghetti P. Hemostatic and fibrinolytic abnormalities in polycystic ovary syndrome. Semin Thromb Hemost. 2014;40(5):600-18. doi: 10.1055/s-0034-1384512, PMID 25000958.
Słopień R, Lewandowski K, Kolacz E, Zawilska K, Warenik-Szymankiewicz A. Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity. Gynecol Endocrinol. 2006 Jan 1;22(11):651-4. doi: 10.1080/09513590601005805, PMID 17145652.
Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: etiology, treatment, and genetics. Metabolism. 2019 Mar 1;92:108-20. doi: 10.1016/j.metabol.2018.11.002, PMID 30445140.
Falsetti L, Gambera A, Andrico S, Sartori E. Acne and hirsutism in polycystic ovary syndrome: clinical, endocrine–metabolic and ultrasonographic differences. Gynecol Endocrinol. 2002 Jan 1;16(4):275-84. doi: 10.1080/gye.16.4.275.284, PMID 12396556.
Ciampelli M, Fulghesu AM, Lanzone A. Comment on ”Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome”. J Clin Endocrinol Metab. 1999 Aug 1;84(8):2974-5. doi: 10.1210/jcem.84.8.5939-3, PMID 10443707.
Wijeyaratne CN, Seneviratne Rde A, Dahanayake S, Kumarapeli V, Palipane E, Kuruppu N et al. Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic. Hum Reprod. 2011 Jan 1;26(1):202-13. doi: 10.1093/humrep/deq310, PMID 21098627.
Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007 Aug 25;370(9588):685-97. doi: 10.1016/S0140-6736(07)61345-2, PMID 17720020.
Boumosleh JM, Grundy SM, Phan J, Neeland IJ, Chang A, Vega GL. Metabolic concomitants of obese and non-obese women with features of polycystic ovarian syndrome. J Endocr Soc. 2017 Dec 1;1(12):1417-27. doi: 10.1210/js.2017-00323, PMID 29264465.
Al-Zubeidi H, Klein KO. Randomized clinical trial evaluating metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome. J Pediatr Endocrinol Metab. 2015 Jul 1;28(7-8):853-8. doi: 10.1515/jpem-2014-0283, PMID 25781525.
Panidis D, Georgopoulos NA, Piouka A, Katsikis I, Saltamavros AD, Decavalas G et al. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. Gynecol Endocrinol. 2011 Aug 1;27(8):587-92. doi: 10.3109/09513590.2010.507283, PMID 20836726.
Gambineri A, Patton L, Altieri P, Pagotto U, Pizzi C, Manzoli L et al. Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study. Diabetes. 2012 Sep 1;61(9):2369-74. doi: 10.2337/db11-1360, PMID 22698921.
Dumesic DA, Lobo RA. Cancer risk and PCOS. Steroids. 2013 Aug 1;78(8):782-5. doi: 10.1016/j.steroids.2013.04.004, PMID 23624028.
Dokras A. Noncontraceptive use of oral combined hormonal contraceptives in polycystic ovary syndrome—risks versus benefits. Fertil Steril. 2016 Dec 1;106(7):1572-9. doi: 10.1016/j.fertnstert.2016.10.027, PMID 27817838.
Eshre R, ASRM. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004 Jan;19(1):41-7. doi: 10.1093/humrep/deh098, PMID 14688154.
Kumar S, Banerjee A, Mahto M, Ranjan A, Singh M, Takhelmayum R. Evaluation of relationship between hyperuricemia and lipid profile. Evaluation. 2018 Jun;4(6).
Park J, Lee S, Kim Y, Choi A, Lee H, Lim J et al. Comparison of four automated carcinoembryonic antigen immunoassays: Advia Centaur XP, ARCHITECT I2000sr, Elecsys E170, and Unicel Dxi800. Ann Lab Med. 2018 Jul;38(4):355-61. doi: 10.3343/alm.2018.38.4.355, PMID 29611386.
Yildiz BO, Haznedaroğlu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab. 2002 Aug 1;87(8):3871-5. doi: 10.1210/jcem.87.8.8716, PMID 12161525.
Franks S. Polycystic ovary syndrome. N Engl J Med. 1995 Sep 28;333(13):853-61. doi: 10.1056/NEJM199509283331307, PMID 7651477.
Dunaif A, Book CB. Insulin resistance in the polycystic ovary syndrome. Clin Res Diabetes Obes. 1997:249-74.
Godtfredsen ACM, Sidelmann JJ, Gram JB, Andersen M, Glintborg D. Fibrin lysability is associated with central obesity and inflammation in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2020 Aug;99(8):1078-84. doi: 10.1111/aogs.13825, PMID 32048272.
Yang YM, Choi EJ. Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome. Ther Clin Risk Manag. 2015;11:1345-53. doi: 10.2147/TCRM.S89737, PMID 26366087.
Essah PA, Arrowood JA, Cheang KI, Adawadkar SS, Stovall DW, Nestler JE. Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertil Steril. 2011 Aug 1;96(2):501-504.e2. doi: 10.1016/j.fertnstert.2011.05.091, PMID 21733508.
Saxena P, Prakash A, Nigam A. Effect of metformin therapy on 2-h post-glucose insulin levels in patients of polycystic ovarian syndrome. J Hum Reprod Sci. 2010 Sep;3(3):139-42. doi: 10.4103/0974-1208.74156, PMID 21234175.
Bhathena RK. Insulin resistance and the long-term consequences of polycystic ovary syndrome. J Obstet Gynaecol. 2011 Feb 1;31(2):105-10. doi: 10.3109/01443615.2010.539722, PMID 21281021.
Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012 Dec 1;33(6):981-1030. doi: 10.1210/er.2011-1034, PMID 23065822.
Srinag L, Maruthy KN, Kareem SK, Siva Kumar AV, Kumar K, Preetham Gurja J. Impact of overweight on cognition and psychomotor skills among children with overweight. Obes Med. 2020 Jun 1;18:100191. doi: 10.1016/j.obmed.2020.100191.
Adali E, Yildizhan R, Kurdoglu M, Bugdayci G, Kolusari A, Sahin HG. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome. Fertil Steril. 2010 Jul 1;94(2):666-72. doi: 10.1016/j.fertnstert.2009.03.037, PMID 19368913.
Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI‐1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf). 1996 Nov;45(5):623-9. doi: 10.1046/j.1365-2265.1996.00863.x, PMID 8977761.
Prüller F, Raggam RB, Posch V, Almer G, Truschnig-Wilders M, Horejsi R et al. Trunk weighted obesity, cholesterol levels and low grade inflammation are main determinants for enhanced thrombin generation. Atherosclerosis. 2012 Jan 1;220(1):215-8. doi: 10.1016/j.atherosclerosis.2011.09.035, PMID 22035573.
Fraison E, Kostova E, Moran LJ, Bilal S, Ee CC, Venetis C et al. Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome. Cochrane Database Syst Rev. 2020 Aug 13;8(8):CD005552. doi: 10.1002/14651858.CD005552.pub3, PMID 32794179.
Published
How to Cite
Issue
Section
Copyright (c) 2023 A. Swathi, Vijayalakshmi, I. Yogananda Reddy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
